27.27, 27.30, 29.26, 29.45, 31.29, 31.87, 35.93, 87.56, 92.76, 92.93,
92.97, 93.02, 94.43, 120.55, 122.40, 122.64, 122.70, 122.75,
122.77, 128.51, 131.40, 131.53, 131.66, 131.76, 143.24, 143.32,
143.41, 143.53. Elemental analysis: calc. for C90H102: C, 91.32; H,
8.68; found: C, 91.31; H, 8.49%. APCI-MS: m/z ¼ 1184.7
([M + H]+, calc. 1184.8).
Pd(PPh3)2Cl2 (13 mg, 0.019 mmol), CuI (13 mg, 0.068 mmol),
and piperidine–THF (2 : 1, 15 mL). Yield: 208 mg (71%) of a pale
yellow solid; phase transitions (ꢁC): Cr 97 N 155 I. H NMR
1
(CDCl3): d ¼ 0.88 (t, J ¼ 6.8 Hz, 6H), 1.23–1.36 (m, 32H), 1.57–
1.66 (m, 4H), 2.62 (t, J ¼ 7.6 Hz, 4H), 2.85 (q, J ¼ 7.6 Hz, 8H),
7.17 (d, J ¼ 8.2 Hz, 4H), 7.39 (s, 4H), 7.45 (d, J ¼ 8.2 Hz, 4H),
7.51 (s, 4H); 13C NMR (CDCl3): d ¼ 14.10, 14.68, 14.73, 22.67,
27.17, 29.24, 29.26, 29.45, 31.29, 31.87, 35.93, 87.52, 90.25, 93.70,
94.50, 120.52, 121.96, 122.96, 123.26, 128.51, 131.41, 131.43,
131.50, 131.55, 143.39, 143.45, 143.55. Elemental analysis: calc.
for C62H70: C, 91.35; H, 8.65; found: C, 91.25; H, 8.45%. APCI-
MS: m/z ¼ 816.2 ([M + H]+, calc. 815.6).
Compound 5a. Synthesized by the procedure described for 1.
Quantities: 16a (210 mg, 0.402 mmol), 10f (356 mg, 1.13 mmol),
Pd(PPh3)2Cl2 (28 mg, 0.040 mmol), CuI (33 mg, 0.17 mmol), and
piperidine (15 mL). Yield: 261 mg (72%) of a pale yellow solid;
1
phase transition (ꢁC): Cr 103 I. H NMR (CDCl3): d ¼ 0.88
(t, J ¼ 6.8 Hz, 6H), 1.03 (t, J ¼ 7.6 Hz, 6H), 1.23–1.36 (m, 32H),
1.57–1.66 (m, 4H), 1.70–1.81 (m, 4H), 2.62 (t, J ¼ 7.6 Hz, 4H),
2.82 (t, J ¼ 7.6 Hz, 4H), 2.86 (q, J ¼ 7.6 Hz, 4H), 2.87 (q, J ¼
7.6 Hz, 4H), 7.17 (d, J ¼ 8.2 Hz, 4H), 7.386 (s, 2H), 7.389 (s, 4H),
7.45 (d, J ¼ 8.2 Hz, 4H); 13C NMR (CDCl3): d ¼ 14.06, 14.10,
14.69, 14.93, 22.66, 23.91, 27.20, 29.24, 29.26, 29.45, 31.29, 31.87,
35.93, 36.28, 87.57, 92.85, 93.02, 94.41, 120.55, 122.45, 122.73,
122.77, 128.51, 131.40, 131.47, 131.66, 132.56, 141.76, 143.13,
143.38, 143.52. Elemental analysis: calc. for C68H82: C, 90.81;
H, 9.19; found: C, 91.12; H, 9.09%. APCI-MS: m/z ¼ 900.3
([M + H]+, calc. 899.6).
Compound 6b. Synthesized by the procedure described for 1.
Quantities: 17b (179 mg, 0.362 mmol), 10f (294 mg, 0.930 mmol),
Pd(PPh3)2Cl2 (18 mg, 0.026 mmol), CuI (17 mg, 0.089 mmol),
and piperidine (20 mL). Yield: 221 mg (70%) of a pale yellow
solid; phase transition (ꢁC): Cr 94 I. 1H NMR (CDCl3): d ¼ 0.88
(t, J ¼ 7.0 Hz, 6H), 1.01 (t, J ¼ 7.2 Hz, 6H), 1.02 (t, J ¼ 7.2 Hz,
6H), 1.23–1.36 (m, 20H), 1.57–1.66 (m, 4H), 1.69–1.80 (m, 8H),
2.62 (t, J ¼ 7.6 Hz, 4H), 2.80 (t, J ¼ 7.6 Hz, 8H), 7.17 (d, J ¼
8.2 Hz, 4H), 7.36 (s, 4H), 7.44 (d, J ¼ 8.2 Hz, 4H), 7.50 (s, 4H);
13C NMR (CDCl3): d ¼ 14.05, 14.10, 22.66, 23.72, 23.77, 29.23,
29.26, 29.45, 31.28, 31.87, 35.93, 36.16, 87.73, 90.47, 93.57, 94.37,
120.55, 122.07, 123.07, 123.28, 128.52, 131.38, 131.40, 132.31,
132.37, 141.93, 142.00, 143.52. Elemental analysis: calc. for
C66H78: C, 90.98; H, 9.02; found: C, 90.98; H, 8.89%. APCI-MS:
m/z ¼ 872.3 ([M + H]+, calc. 871.6).
Compound 5b. Synthesized by the procedure described for 1.
Quantities: 16b (204 mg, 0.336 mmol), 10f (285 mg, 0.901 mmol),
Pd(PPh3)2Cl2 (21 mg, 0.030 mmol), CuI (20 mg, 0.11 mmol), and
piperidine (20 mL). Yield: 223 mg (68%) of a pale yellow solid;
1
phase transition (ꢁC): Cr 91 I. H NMR (CDCl3): d ¼ 0.89 (t,
J ¼ 6.8 Hz, 12H), 1.23–1.37 (m, 40H), 1.47–1.38 (m, 4H), 1.57–
1.66 (m, 4H), 1.66–1.76 (m, 4H), 2.62 (t, J ¼ 7.6 Hz, 4H), 2.83
(t, J ¼ 7.6 Hz, 4H), 2.86 (q, J ¼ 7.6 Hz, 4H), 2.87 (q, J ¼ 7.6 Hz,
4H), 7.17 (d, J ¼ 8.2 Hz, 4H), 7.38 (s, 2H), 7.39 (s, 4H), 7.45
(d, J ¼ 8.2 Hz, 4H); 13C NMR (CDCl3): d ¼ 14.10, 14.70, 14.88,
22.66, 27.19, 29.24, 29.26, 29.34, 29.45, 30.81, 31.29, 31.81, 31.87,
34.31, 35.93, 87.58, 92.84, 93.04, 94.40, 120.55, 122.48, 122.71,
122.73, 128.51, 131.40, 131.44, 131.66, 132.45, 142.00, 143.12,
143.37, 143.52. Elemental analysis: calc. for C74H94: C, 90.37; H,
9.63; found: C, 90.39; H, 9.53%. APCI-MS: m/z ¼ 984.6
([M + H]+, calc. 983.7).
Compound 7a. Synthesized by the procedure described for 1.
Quantities: 18a (156 mg, 0.408 mmol), 10f (311 mg, 0.984 mmol),
Pd(PPh3)2Cl2 (15 mg, 0.021 mmol), CuI (17 mg, 0.089 mmol),
and piperidine–THF (1 : 1, 20 mL). Yield: 231 mg (75%) of
1
a white solid; phase transitions (ꢁC): Cr 158 N 261 I. H NMR
(CDCl3): d ¼ 0.88 (t, J ¼ 6.8 Hz, 6H), 1.23–1.36 (m, 26H), 1.57–
1.66 (m, 4H), 2.62 (t, J ¼ 7.6 Hz, 4H), 2.86 (t, J ¼ 7.6 Hz, 4H),
7.17 (d, J ¼ 8.0 Hz, 4H), 7.39 (s, 2H), 7.45 (d, J ¼ 8.0 Hz, 4H),
7.50 (s, 8H); 13C NMR (CDCl3): d ¼ 14.10, 14.69, 22.66, 27.15,
29.23, 29.25, 29.44, 31.23, 31.86, 35.93, 88.51, 89.99, 91.60, 93.97,
120.10, 122.44, 122.98, 123.40, 128.51, 131.39, 131.50, 131.53,
131.60, 143.50, 143.73. Elemental analysis: calc. for C58H62: C,
91.77; H, 8.23; found: C, 91.43; H, 8.00%. APCI-MS: m/z ¼ 760.0
([M + H]+, calc. 759.5).
Compound 5c. Synthesized by the procedure described for 1.
Quantities: 16c (233 mg, 0.385 mmol), 10f (348 mg, 1.10 mmol),
Pd(PPh3)2Cl2 (21 mg, 0.030 mmol), CuI (22 mg, 0.12 mmol), and
piperidine (10 mL). Yield: 281 mg (76%) of a pale yellow solid;
phase transition (ꢁC): Cr 102 I. 1H NMR (CDCl3): d ¼ 0.88 (t, J ¼
6.8 Hz, 6H), 1.01 (t, J ¼ 7.6 Hz, 6H), 1.017 (t, J ¼ 7.6 Hz, 6H),
1.021 (t, J ¼ 7.6 Hz, 6H), 1.23–1.36 (m, 20H), 1.57–1.66 (m, 4H),
1.70–1.81 (m, 12H), 2.62 (t, J ¼ 7.6 Hz, 4H), 2.77–2.85 (m, 12H),
7.17 (d, J ¼ 8.2 Hz, 4H), 7.37 (s, 4H), 7.38 (s, 2H), 7.44 (d, J ¼ 8.2
Hz, 4H); 13C NMR (CDCl3): d ¼ 14.01, 14.07, 14.10, 22.66,
23.75, 23.79, 29.24, 29.26, 29.45, 31.29, 31.87, 35.93, 36.15, 36.20,
87.79, 92.89, 93.07, 94.26, 120.59, 122.56, 122.81, 122.83, 128.52,
131.37, 132.27, 132.55, 141.61, 141.64, 141.91, 143.50. Elemental
analysis: calc. for C72H90: C, 90.51; H, 9.49; found: C, 90.58; H,
9.39%. APCI-MS: m/z ¼ 956.5 ([M + H]+, calc. 955.7).
Compound 7b. Synthesized by the procedure described for 1.
Quantities: 18b (157 mg, 0.383 mmol), 10f (328 mg, 1.04 mmol),
Pd(PPh3)2Cl2 (14 mg, 0.020 mmol), CuI (17 mg, 0.089 mmol),
and piperidine–THF (1 : 1, 20 mL). Yield: 221 mg (73%) of
ꢁ
1
a white solid; phase transitions ( C): Cr 140 N 209 I. H NMR
(CDCl3): d ¼ 0.88 (t, J ¼ 7.0 Hz, 6H), 1.01 (t, J ¼ 7.6 Hz, 6H),
1.23–1.36 (m, 20H), 1.57–1.66 (m, 4H), 1.75 (tq, J ¼ 7.6 Hz, 8H),
2.61 (t, J ¼ 7.6 Hz, 4H), 2.80 (t, J ¼ 7.6 Hz, 4H), 7.17
(d, J ¼ 8.2 Hz, 4H), 7.37 (s, 2H), 7.45 (d, J ¼ 8.2 Hz, 4H), 7.47–
7.52 (m, 8H); 13C NMR (CDCl3): d ¼ 14.04, 14.10, 22.67, 23.74,
29.24, 29.26, 29.44, 31.24, 31.87, 35.93, 36.14, 88.51, 90.21, 91.60,
93.84, 120.10, 122.56, 123.01, 123.28, 128.51, 131.35, 131.51,
131.53, 132.43, 142.04, 143.73. Elemental analysis: calc. for
C60H66: C, 91.55; H, 8.45; found: C, 91.52; H, 8.27%. APCI-MS:
m/z ¼ 788.1 ([M + H]+, calc. 787.5).
Compound 6a. Synthesized by the procedure described for 1.
Quantities: 17a (158 mg, 0.361 mmol), 10f (258 mg, 0.816 mmol),
This journal is ª The Royal Society of Chemistry 2008
J. Mater. Chem., 2008, 18, 4468–4477 | 4471